Hopp til innhold
NHI.no
Annonse

Astmamedisiner var på dopinglisten

Innhold i artikkelen

Studier har vist at forbruk av medisiner mot astma er høyt hos eliteidrettsutøvere. Flere av astmamedisinene var på World Anti-Doping Agency (WADA) sin liste over forbudte stoffer fram til 2011. WADAs dopingregler gjelder over hele verden. I Norge er det Antidoping Norge som håndhever disse reglene.

WADA-regulering av astmamedisiner type beta-2 agonister, per 2020: Alle beta-2 agonister er forbudt. Unntak: inhalert salbutamol (korttidsvirkende beta-2 agonist), maks. 1600 mcg pr. døgn, fordelt på flere enkeltdoser, maks. 800 mcg/12 timer. Ved bruk av større doser, annen administrasjonsmåte (f.eks. forstøverapparat), eller ved bruk av annen korttidsvirkende beta-2 agonist (f.eks. terbutalin) må atleten søke om medisinsk fritak (se under).

Det finnes også unntak med dosebegrensning for tre langtidsvirkende beta-2 agonister. Ved astma må alle som behandles med beta-2 agonist også få et inhalasjonssteroid. Idrettsutøvere som har anstrengelsesutløst bronkospasme uten samtidig astma, kan eventuelt behandles med salbutamol alene, så lenge utøveren ikke har daglig behov for medikamentet. I så fall er det anbefalt å behandle med inhalasjonssteroid i tillegg.

Bruk av steroider (glukokortikoider) som tabletter, stikkpiller eller per sprøyte er forbudt. Inhalasjonssteroider som markedsføres i Norge per juli 2021 til bruk som forebyggende astmabehandling i vanlige doser, er tillatt uten søknad om fritak.

Medikamentet montelukast, en annen forebyggende astmamedisin, står per 2020 ikke på WADAs dopingliste.

NB! Dosering over tillatte maksimale doser krever søknad om medisinsk fritak på forespørsel.

Antidoping Norge tilbyr et nyttig legemiddelsøk og mye relevant tilleggsinformasjon på sin nettside.

Idrettsutøvere som deltar i konkurranser i regi av nasjonale eller internasjonale idrettsorganisasjoner, må sette seg inn i regelverket for sitt forbund.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Bronkospasme, anstrengelsesutløst . Referanselisten for dette dokumentet vises nedenfor

  1. Smoliga JM, Mohseni ZS, Berwager JD, et al. Common causes of dyspnoea in athletes: a practical approach for diagnosis and management. Breathe (Sheff) 2016 Jun; 12(2): e22-37. pmid:27408644 PubMed
  2. Weiler JM, Anderson SD, Randolph C, et al; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. Ann Allergy Asthma Immunol 2010;105(suppl):S1-47
  3. Smoliga JM, Weiss P, Rundell KW. Exercise induced bronchoconstriction in adults: evidence based diagnosis and management. BMJ 2016; 352: h6951. pmid:26762594 PubMed
  4. Weiler JM, Brannan JD, Randolph CC, Hallstrand TS, Parsons J, Silvers W, Storms W, Zeiger J, Bernstein DI, Blessing-Moore J, Greenhawt M, Khan D, Lang D, Nicklas RA, Oppenheimer J, Portnoy JM, Schuller DE, Tilles SA, Wallace D. Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol. 2016 Nov;138(5):1292-1295.e36. Epub 2016 Sep 21. PMID: 27665489. PubMed
  5. Weiss P, Rundell KW. Imitators of exercise-induced bronchoconstriction. Allergy Asthma Clin Immunol. 2009; 5(1): 7. pmid:20016690 PubMed
  6. de Aguiar KB, Anzolin M, Zhang L. Global prevalence of exercise-induced bronchoconstriction in childhood: A meta-analysis. Pediatr Pulmonol 2018; Jan 24: epub ahead of print. pmid:29364581 PubMed
  7. Molis MA, Molis WE. Exercise-induced bronchospasm. Sports Health 2010 Jul; 2(4): 311-17. doi:10.1177/1941738110373735 DOI
  8. Wilber RL, Rundell KW, Szmedra L, Jenkinson DM, Im J, Drake SD. Incidence of exercise-induced bronchospasm in Olympic winter sport athletes. Med Sci Sports Exerc 2000; 32: 732-7. PubMed
  9. Parsons JP, Mastronarde JG. Exercise-induced bronchoconstriction in athletes. Chest 2005; 128: 3966-74. PubMed
  10. Weiler JM, Hallstrand TS, Parsons JP, et al. Improving screening and diagnosis of exercise-induced bronchoconstriction: a call to action. J Allergy Clin Immunol Pract 2014; 2(3): 275-80. pmid:24811017 PubMed
  11. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Resp Crit Care Med 2013. doi:10.1164/rccm.201303-0437ST DOI
  12. Weiler JM, Bonini S, Coifman R, et al. Ad Hoc Committee of Sports Medicine Committee of American Academy of Allergy, Asthma & Immunology. American Academy of Allergy, Asthma & Immunology Work Group report: exercise-induced asthma. J Allergy Clin Immunol 2007; 119: 1349-58. PubMed
  13. Carlsen KH, Anderson SD, Bjermer L, et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 2008 Apr; 63(4): 387-403. pmid:18315727 PubMed
  14. Pasnick SD, Carlos WG 3rd, Arunachalam A, et al. Exercise-induced bronchoconstriction. Ann Am Thorac Soc 2014 Dec; 11(10): 1651-2. pmid:25549031 PubMed
  15. Røksund OD, Heimdal JH, Clemm H. Exercise inducible laryngeal obstruction: diagnostics and management. Paediatr Respir Rev 2016 ; Jul 18: S1526-0542. doi:10.1016/j.prrv.2016.07.003 DOI
  16. Nielsen EW, Hull JH, Backer V. High prevalence of exercise-induced laryngeal obstruction in athletes. Med Sci Sports Exerc 2013 Nov; 45(11): 2030-5. pmid:23657163 PubMed
  17. Krafczyk MA, Asplund CA. Exercise-induced bronchoconstriction: diagnosis and management. Am Fam Physician 2011: 84; 427-34.
  18. Sonna LA, Angel KC, Sharp MA, Knapik JJ, Patton JF, Lilly CM. The prevalence of exercise-induced bronchospasm among US Army recruits and its effects on physical performance. Chest 2001;119:1676-84. PubMed
  19. Latorre-Román PÁ, Navarro-Martínez AV, García-Pinillos F. The effectiveness of an indoor intermittent training program for improving lung function, physical capacity, body composition and quality of life in children with asthma. J Asthma 2014 Jun; 51(5): 544-51. pmid:24471516 PubMed
  20. Carlsen K-H. Fysisk aktivitet og luftveissykdommer, astma og allergi. Tidsskr Nor Lægeforen 2000; 120: 3305-9. Tidsskrift for Den norske legeforening
  21. Tan RA, Spector SL. Exercise-induced asthma. Sports Med 1998;25:1-6. PubMed
  22. Stickland MK, Rowe BH, Spooner CH, et. al. Effect of warm-up exercise on exercise-induced bronchoconstriction. Med Sci Sports Exerc 2012 Mar; 44(3): 383-91. pmid:21811185 PubMed
  23. Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma. Chest 2006; 129: 1188-93. PubMed
  24. World Anti-Doping Agency. Prohibited at all times. Beta-2 agonists. www.wada-ama.org
  25. Antidoping Norge. Regler. Dopinglisten. Dopinggruppe S3: beta-2 agonister antidoping.no
  26. O'Byrne PM, Barnes PJ, Wood RA. Exercise-induced bronchoconstriction. www.uptodate.com , sist oppdatert 23.10.2019. Siden besøkt 6.8.2020. UpToDate
  27. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346:201-6. PubMed
  28. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from www.ginasthma.org ginasthma.org
  29. Antidoping Norge. Legemiddelsøk. Symbicort. Siden besøkt 21.05.2021. www.antidoping.no
  30. Koh M, Tee A, Lasserson T, Irving L. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev, issue 3, 2007. The Cochrane Library
  31. Philip G, Pearlman DS, Villarán C, et al. Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest 2007; 132: 875-83. PubMed
  32. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52. New England Journal of Medicine
  33. Raissy HH, Harkins M, Kelly F, Kelly HW. Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. Pharmacotherapy 2008; 28: 287-94. PubMed
  34. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132: 97-104. Annals of Internal Medicine
  35. Tan RA, Spector SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002;89:226-35. PubMed
  36. Wilkinson M, Hart A, Milan SJ, et al. Vitamins C and E for asthma and exercise-induced bronchoconstriction. Cochrane Database Syst Rev. 2014 Jun; 17;(6): CD010749. doi:10.1002/14651858.CD010749.pub2. DOI
Annonse
Annonse